Prescription medicine

Flortaucipir f 18 Brand names: Tauvid

Flortaucipir f 18 (Tauvid) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the flortaucipir f 18 FDA label on DailyMed (effective December 30, 2025, Eli Lilly and Company); the NDA 212123 record on Drugs@FDA; every flortaucipir f 18 label on DailyMed.

Highlights of the record

FDA label of December 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).

Forms and strengths

Injection (solution).

On the market

Earliest approval on file: May 28, 2020 Tauvid, Avid Radiopharms Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: May 26, 2032 Tauvid injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 1 through July 30, 2026

What is flortaucipir f 18 used for?

From the label: indications and usage
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). TAUVID is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). […]

Source: FDA drug label (TAUVID), NDA212123 (Avid Radiopharms Inc), as published by Eli Lilly and Company, effective December 30, 2025 (SPL set b483abad-5230-462a-adfb-1a65160f01d0), via openFDA; the full label on DailyMed

Is there a generic for flortaucipir f 18 (Tauvid)?

No generic flortaucipir f 18 is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 1 patent for Tauvid injection: the compound patent runs to May 26, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2020 earliest approval on file
2032 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for flortaucipir f 18?

The FDA Adverse Event Reporting System holds 1 report that list flortaucipir f 18 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Incorrect Dose Administered (a use or a product term, not a reaction)1

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Flortaucipir f 18 side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other